Top

PharmacoEconomics

Published in:

01-10-2009 | Review Article

Budget-Impact Analyses

A Critical Review of Published Studies

Authors: Dr Ewa Orlewska, Laszlo Gulácsi

Published in: PharmacoEconomics | Issue 10/2009

Abstract

This article reviews budget-impact analyses (BIAs) published to date in peer-reviewed bio-medical journals with reference to current best practice, and discusses where future research needs to be directed.

Published BIAs were identified by conducting a computerized search on PubMed using the search term ‘budget impact analysis’. The years covered by the search included January 2000 through November 2008. Only studies (i) named by authors as BIAs and (ii) predicting financial consequences of adoption and diffusion of a new health intervention(s) within a specific healthcare setting were included. Relevant studies were evaluated according to the checklist that focuses on issues unique to BIA, highlighting areas of agreement or dissent between published studies and methodological guidelines.

A total of 34 studies met the inclusion criteria, the majority published in 2007–8. Of these, 41% were from the US, 54% were prepared for pharmaceuticals and 65% had BIA as their main aim. The published BIAs were heterogeneous in respect of methods for deriving budget-impact estimates, time horizon and population. There is fairly good agreement between published studies and methodological guidelines within the scope of perspective, comparator, cost included and data sources. Specific issues that need to be addressed and/or improved are reporting format, sensitivity analysis and discounting.

The results indicate that, recently, BIAs have appeared more frequently in peer-reviewed journals, providing stimulus to development, validation and dissemination of methods. Many published studies fail to reach the desired quality, but this situation should change with good research practice principles that will help codify and clarify important issues and promote standardization and transparency. Future research needs to be directed to quality assurance of published BIAs and investment in data collection for parameters specific to BIAs.

Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices. Budget impact analysis. Value Health 2007 Sep-Oct; 10 (5): 336–47PubMedCrossRef

Mauskopf J. Prevalence-based economic evaluation. Value Health 1998; 1 (4): 251–9PubMedCrossRef

Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics 2001; 19 (6): 609–21PubMedCrossRef

Commonwealth Department of Health and Ageing. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Canberra (ACT): Commonwealth Department of Health and Ageing, Sep 2002 [online]. Available from URL: http://www.health.gov.au/internet/main/publishing.nsf/Content/health-pbs-general-pubs-guidelines-index.htm/FILE/guidelines.pdf [Accessed 2008 Nov]

Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada. 2nd ed. Ottawa (ON): CCOHTA, 1997 Nov [online]. Available from URL: http://www.acmts.ca/index.php/en/hta/reports-publications/search/publication/35 [Accessed 2005 Aug]

Academy of Managed Care Pharmacy. Format for formulary submissions, version 2.1. 2001 Apr [online]. Available from URL: http://www.fmcpnet.org/data/resource/Format~Version_2_1~Final_Final.pdf [Accessed 2008 Nov]

National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2004 Apr [online]. Available from URL: http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf [Accessed 2008 Nov]

Annemans L, Crott R, Degraeve D, et al. Recommended structure for reporting economic evaluation on pharmaceuticals in Belgium. Pharm World Sci 2002; 24 (1): 5–7PubMedCrossRef

French guidelines for the economic evaluation of health care technologies. Paris: Collège des Économistes de la Santé, 2004 Sep [online]. Available from URL: http://www.ispor.org/PEguidelines/source/France_Guidelines_HE_Evaluation.pdf [Accessed 2008 Nov]

10.

Szende A, Mogyorosy Z, Muszbek N, et al. Methodological guidelines for conducting economic evaluation of healthcare interventions in Hungary: a Hungarian proposal for methodology standards. Eur J Health Econ 2002; 3: 196–206CrossRef

11.

Capri S, Ceci A, Terranova L, et al. Guidelines for economic evaluations in Italy: recommendations from the Italian Group of Pharmacoeconomic Studies. Drug Inf J 2001; 35: 189–2001CrossRef

12.

Orlewska E, Mierzejewski P. Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries. Value Health 2004; 7 (1): 1–10PubMedCrossRef

13.

Guidelines for the submission of a request to include a pharmaceutical product in the national list of health services. Version 4. Jerusalem: April 2002 [online]. Available from URL: http://www.ispor.org/PEguidelines/source/PE%20GUIDELINES_Israel.pdf [Accessed 2008 Nov]

14.

Marshall DA, Douglas PR, Drummond MF, et al. Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. Pharmacoeconomics 2008; 26 (6): 477–95PubMedCrossRef

15.

Launois R, Payet S, Saidenberg-Kermanac’h N, et al. Budget impact model of rituximab after failure of one or more TNF alpha inhibitor therapies in the treatment of rheumatoid arthritis. Joint Bone Spine 2008; 75 (6): 688–95PubMedCrossRef

16.

Tosteson ANA, Burge RT, Marshall DA, et al. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manag Care 2008 Sep; 14 (9): 605–15PubMed

17.

Danese MD, Reyes C, Northridge K, et al. Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer. Clin Ther 2008 Apr; 30 (4): 775–84PubMedCrossRef

18.

Krysanov IS, Kulikov AIu. Methodology of new pharmacoeconomic method ‘impact on hospital budget’ by the example of local hemostatic agents in abdominal surgery [in Russian]. Khirurgiia (Mosk) 2008; (3): 58–63

19.

Chuck AW, Hailey D, Jacobs P, et al. Cost-effectiveness and budget impact of adjunctive hyperbaric oxygen therapy for diabetic foot ulcers. Int J Technol Assess Health Care 2008 Spring; 24 (2): 178–83PubMedCrossRef

20.

Lee WC, Yeh YC, Lacy BE, et al. Timely confirmation of gastro-esophageal reflux disease via pH monitoring: estimating budget impact on managed care organizations. Curr Med Res Opin 2008 May; 24 (5): 1317–27PubMedCrossRef

21.

Mar J, Sainz-Ezkerra M, Miranda-Serrano E. Calculation of prevalence with Markov models: budget impact analysis of thrombolysis for stroke. Med Decis Making 2008 Jul-Aug; 28 (4): 481–90PubMedCrossRef

22.

Guest JF, Valovirta E. Modelling the resource implications and budget impact of new reimbursement guidelines for the management of cow milk allergy in Finland. Curr Med Res Opin 2008 Apr; 24 (4): 1167–77PubMedCrossRef

23.

Noskin GA, Rubin RJ, Schentag JJ, et al. Budget impact analysis of rapid screening for Staphylococcus aureus colonization among patients undergoing elective surgery in US hospitals. Infect Control Hosp Epidemiol 2008 Jan; 29 (1): 16–24PubMedCrossRef

24.

Heeg BMS, Antunes J, Figueira ML, et al. Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise. Curr Med Res Opin 2008 Feb; 24 (2): 349–58PubMedCrossRef

25.

Kondo M, Hoshi SL, Ishiguro H, et al. Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan. Breast Cancer Res Treat 2008 Nov; 112 (1): 175–87PubMedCrossRef

26.

Ehlers L, Müskens WM, Jensen LG, et al. National use of thrombolysis with alteplase for acute ischaemic stroke via telemedicine in Denmark: a model of budgetary impact and cost effectiveness. CNS Drugs 2008; 22 (1): 73–81PubMedCrossRef

27.

Dal Negro R, Eandi M, Pradelli L, et al. Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and bronchodilators for severe and very severe COPD patients. Int J Chron Obstruct Pulmon Dis 2007; 2 (2): 169–76

28.

Walt JG, Wilensky JT, Fiscella R, et al. Refill rates and budget impact of glaucoma lipid therapy: a retrospective database analysis. Clin Drug Investig 2007; 27 (12): 819–25PubMedCrossRef

29.

Machado M, Iskedjian M, Ruiz IA, et al. The economic impact of introducing serotonin-noradrenaline reuptake inhibitors into the Brazilian national drug formulary: cost-effectiveness and budget-impact analyses. Pharmacoeconomics 2007; 25 (11): 979–90PubMedCrossRef

30.

Spiegel BM, Esrailian E, Eisen G. The budget impact of endoscopic screening for esophageal varices in cirrhosis. Gastrointest Endosc 2007 Oct; 66 (4): 679–92PubMedCrossRef

31.

Huang E, Esrailian E, Spiegel BM. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy: a decision analysis. Aliment Pharmacol Ther 2007 Oct 15; 26 (8): 1147–61PubMedCrossRef

32.

Malone DC. A budget-impact and cost-effectiveness model for second-line treatment of major depression. J Manag Care Pharm 2007 Jul; 13 (6 Suppl. A): S8–18

33.

Berto P, Gallio D, Principi N. Budgetary impact of pneumococcal conjugate vaccination of newborns [in Italian]. Ann Ig 2007 May-Jun; 19 (3): 281–91PubMed

34.

Castillón Vela IT, Redondo González E, Linares Quevedo AI, et al. Outpatient female stress urinary incontinence surgery: budget impact study [in Spanish]. Arch Esp Urol 2007 Apr; 60 (3): 267–272PubMedCrossRef

35.

Araújo DV, Lima VC, Ferraz MB. Impact analysis of drug-eluting stent in the unified health system budget. Arq Bras Cardiol 2007 Apr; 88 (4): 458–63PubMedCrossRef

36.

Izuel Rami M, Gómez Barrera M, Villar Fernández I, et al. Budget impact analysis of a blood saving program for urgent traumatological surgery [in Spanish]. Med Clin (Barc) 2007 Jan 13; 128 (1): 7–11CrossRef

37.

Casado Gómez MA, Alvarez-Rubio L, Miró Manero S, et al. Budget impact analysis of the treatment of chronic hepatitis C in a hospital [in Spanish]. Farm Hosp 2006 Sep-Oct; 30 (5): 291–299PubMedCrossRef

38.

Ackroyd R, Mouiel J, Chevallier JM, et al. Cost-effectiveness and budget impact of obesity surgery in patients with type-2 diabetes in three European countries. Obes Surg 2006 Nov; 16 (11): 1488–503PubMedCrossRef

39.

Caro JJ, Huybrechts KF, Xenakis JG, et al. Budgetary impact of treating acute bipolar mania in hospitalized patients with quetiapine: an economic analysis of clinical trials. Curr Med Res Opin 2006 Nov; 22 (11): 2233–42PubMedCrossRef

40.

Russell S, Antoñanzas F, Mainar V. Economic impact of the taxus coronary stent: implications for the Spanish healthcare system. Rev Esp Cardiol 2006 Sep; 59 (9): 889–96PubMedCrossRef

41.

Ramsey SD, Clarke L, Kamath TV, et al. Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a US health insurance plan. J Manag Care Pharm 2006 Jul-Aug; 12 (6): 472–8PubMed

42.

Spiegel BM, Dulai GS, Lim BS, et al. The cost-effectiveness and budget impact of intravenous versus oral proton pump inhibitors in peptic ulcer hemorrhage. Clin Gastroenterol Hepatol 2006 Aug; 4 (8): 988–97PubMedCrossRef

43.

Buti M, Casado MA, Fosbrook L, et al. Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1. Pharmacoeconomics 2005; 23 (10): 1043–55PubMedCrossRef

44.

Smith DG, Cerulli A, Frech FH. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis. Clin Ther 2005 Jun; 27 (6): 951–9PubMedCrossRef

45.

Sørensen J, Andersen LS. The case of tumour necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis: a budget impact analysis. Pharmacoeconomics 2005; 23 (3): 289–98PubMedCrossRef

46.

Chang J, Sung J. Health plan budget impact analysis for pimecrolimus. J Manag Care Pharm 2005 Jan-Feb; 11 (1): 66–73PubMed

47.

Bloom MA, Barghout V, Kahler KH, et al. Budget impact of tegaserod on a Managed Care Organization formulary. Am J Manag Care 2005; 11: S27–34

48.

Marchetti M, Caruggi M, Colombo G. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service. Clin Ther 2004 Sep; 26 (9): 1546–61PubMedCrossRef

49.

Mauskopf JA, Earnshaw S, Mullins CD. Budget impact analysis: review of the state of art. Expert Rev Pharmacoeconomics Outcomes Res 2005; 5 (1): 65–79CrossRef

50.

United States National Library of Medicine; National Institutes of Health. International Committee of Medical Journal Editors (ICMJE) uniform requirements for manuscripts submitted to biomedical journals: sample references [online]. Available from URL: http://www.icmje.org/ [Accessed 2009 Aug 24]

Title: Budget-Impact Analyses
A Critical Review of Published Studies
Authors: Dr Ewa Orlewska
Laszlo Gulácsi
Publication date: 01-10-2009
Publisher: Springer International Publishing
Published in: PharmacoEconomics / Issue 10/2009
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI: https://doi.org/10.2165/11313770-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Budget-Impact Analyses

A Critical Review of Published Studies

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2009

Economic Evaluation and Cost-Effectiveness Thresholds

New Anticoagulants for the Prevention of Deep Venous Thrombosis

30 Years of Pharmaceutical Cost-Utility Analyses

Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective

A Cost-Effectiveness Model Comparing Rivaroxaban and Dabigatran Etexilate with Enoxaparin Sodium as Thromboprophylaxis after Total Hip and Total Knee Replacement in the Irish Healthcare Setting

An Economic Evaluation of Docetaxel and Paclitaxel Regimens in Metastatic Breast Cancer in the UK